Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

類似資料

• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
  著者:: Zeybek, Burak, 等
  出版事項: (2020)
• Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
  著者:: Emanuele Perrone, 等
  出版事項: (2020-02-01)
• Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
  著者:: Lopez, Salvatore, 等
  出版事項: (2020)
• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
  著者:: Emanuele Perrone, 等
  出版事項: (2020-03-01)
• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
  著者:: Perrone, Emanuele, 等
  出版事項: (2020)